Asahi Kasei Pharma’s licensing partner, Dong-A ST Co., Ltd. (Dong-A ST), has launched the sale of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: Teribone™ 56.5 µg subcutaneous injection) in Korea on March 28, 2016.

Asahi Kasei Pharma and Dong-A ST concluded a license agreement in October 2014 granting Dong-A ST exclusive rights for the development and sale of Teribone™ in Korea, and Dong-A ST obtained approval in November 2015 from Korea’s Ministry of Food and Drug Safety (MFDS) for the sale of Teribone™ for the treatment of osteoporosis in postmenopausal women at high risk of bone fracture.

The number of patients who suffer from osteoporosis in Korea is increasing as the population ages. Since osteoporosis carries an increased risk of vertebral and femoral fracture, with a high probability of resulting in confinement to bed, the implementation of effective measures against osteoporosis is an important social issue in Korea.

Asahi Kasei Pharma believes that Dong-A ST, with its wealth of experience and strong track record in the field of orthopedics, is well positioned to quickly facilitate the widespread use of Teribone™ in Korea, making a significant contribution to the treatment of osteoporosis.

Corporate profile of Dong-A ST Co., Ltd.